Amgen Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Amgen Inc. (NASDAQ AMGN) opened at 185.79 on Wednesday. The firm’s 50-day moving average is $182.35 and its 200-day moving average is $170.56. The firm has a market cap of $135.57 billion, a price-to-earnings ratio of 16.92 and a beta of 1.36. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.84 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post $12.58 earnings per share for the current year.
Several equities research analysts have issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. Bank of America Corporation boosted their price objective on shares of Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 5th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and issued a $196.00 price objective (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. Finally, Mizuho reissued a “buy” rating and issued a $198.00 price objective on shares of Amgen in a research report on Friday, October 6th. Ten investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $189.99.
Large investors have recently modified their holdings of the company. TrimTabs Asset Management LLC lifted its position in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC lifted its position in shares of Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its position in shares of Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. Phocas Financial Corp. purchased a new stake in shares of Amgen during the 2nd quarter worth approximately $110,000. Finally, American Beacon Advisors Inc. purchased a new stake in shares of Amgen during the 1st quarter worth approximately $106,000. Institutional investors and hedge funds own 78.10% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.